U.S. markets closed
  • S&P 500

    3,768.47
    -51.25 (-1.34%)
     
  • Dow 30

    30,924.14
    -345.95 (-1.11%)
     
  • Nasdaq

    12,723.47
    -274.28 (-2.11%)
     
  • Russell 2000

    2,146.92
    -60.87 (-2.76%)
     
  • Crude Oil

    64.04
    +2.76 (+4.50%)
     
  • Gold

    1,696.00
    -19.80 (-1.15%)
     
  • Silver

    25.34
    -1.04 (-3.95%)
     
  • EUR/USD

    1.1975
    -0.0092 (-0.77%)
     
  • 10-Yr Bond

    1.5500
    +0.0800 (+5.44%)
     
  • GBP/USD

    1.3897
    -0.0056 (-0.40%)
     
  • USD/JPY

    107.9680
    +0.9660 (+0.90%)
     
  • BTC-USD

    47,982.28
    -2,561.38 (-5.07%)
     
  • CMC Crypto 200

    960.96
    -26.25 (-2.66%)
     
  • FTSE 100

    6,650.88
    -24.59 (-0.37%)
     
  • Nikkei 225

    28,930.11
    -628.99 (-2.13%)
     

Catabasis (CATB) Beats Earnings in Q4, Revenues Nil

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
  • Oops!
    Something went wrong.
    Please try again later.

Catabasis Pharmaceuticals, Inc. CATB is a clinical-stage biopharmaceutical company focused on developing innovating treatments. The company’s lead pipeline candidate, edasalonexent, is being developed for treating Duchenne muscular dystrophy (“DMD”) in a late-stage study.

Catabasis’ earnings track record has been mixed so far. Over the four trailing quarters, the company posted an average positive earnings surprise of 18.11%, beating estimates in three quarters and missing the same once.

Currently, Catabasis has a Zacks Rank #2 (Buy) but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings Beat: Catabasis reported a loss of 85 cents per share which was narrower than the Zacks Consensus Estimate of loss of 93 cents.

No Revenues: Catabasis recorded no revenues in the quarter. However, revenues in the year-ago quarter were $0.25 million.

Key Stats: General and administrative expenses were up 41% at $2.4 million while research & development expenses decreased 7.5% to $3.7 million. The company ended 2018 with $37.6 million cash, cash equivalents and short-term investments. In February 2019, the company recorded net proceeds of $18.5 million from sale of its common stock.

Share Price Impact:Shares were up 2% in pre-market trading.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.

This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

See their latest picks free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Catabasis Pharmaceuticals, Inc. (CATB) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research